This meeting is sponsored by:
OVERVIEW
NOTE: This will be held as an online meeting. Details of how to attend will be sent to delegates after registration.
A move away from more “traditional” early phase clinical trial designs and incorporation of biomarkers
is increasingly critical for taking go/no-go decisions during drug development to avoid costly late stage
failures. Both in terms of financial cost and, more importantly, the cost to patients by being given
ineffective experimental medicines.
Adoption of more innovative study designs have several advantages including flexibility, efficient
use of patient numbers at sub-optimal doses, speed and an ability to allow adaptation to the trial and/or
statistical procedures after initiation without undermining validity and integrity. In addition, it is important
to seek involvement of patient advocates early in the clinical trial design process to ensure that patient
needs are met and to avoid poor accrual and compliance.
Inclusion of well-defined pharmacodynamic and phenotypic biomarkers can also help to aid the critical
decision-making process by showing whether the drug is behaving as expected from a biological perspective and
take decisions on recommended dose(s) for further development. This type of data can provide the confidence to
continue clinical development even in the absence of significant clinical efficacy in these early stages.
This virtual, half-day meeting is aimed at students, clinicians and practicing professionals from
academia and industry looking to gain an understanding of how these designs and concepts are being applied
across many therapeutic areas, including oncology, fibrosis, respiratory and inflammatory diseases. Online
networking facilities will be available.
Confirmed Speakers: